Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 2
1974 22
1975 64
1976 52
1977 96
1978 61
1979 101
1980 73
1981 95
1982 133
1983 118
1984 117
1985 193
1986 145
1987 136
1988 155
1989 184
1990 174
1991 178
1992 229
1993 230
1994 244
1995 256
1996 304
1997 277
1998 319
1999 271
2000 277
2001 279
2002 292
2003 239
2004 248
2005 290
2006 262
2007 281
2008 297
2009 263
2010 273
2011 304
2012 284
2013 287
2014 300
2015 340
2016 353
2017 315
2018 292
2019 156
2020 6
Text availability
Article attribute
Article type
Publication date

Search Results

9,373 results
Results by year
Filters applied: . Clear all
Page 1
Evaluation and Management of Penicillin Allergy: A Review
Shenoy ES, et al. JAMA 2019 - Review. PMID 30644987
Currently, the rate of IgE-mediated penicillin allergies is decreasing, potentially due to a decreased use of parenteral penicillins, and because severe anaphylactic reactions to oral amoxicillin are rare. ...Direct amoxicillin challenge is appropriate for patients with low-risk allergy histories. Moderate-risk patients can be evaluated with penicillin skin testing, which carries a negative predictive value that exceeds 95% and approaches 100% when combined with amoxicillin challenge. ...
Currently, the rate of IgE-mediated penicillin allergies is decreasing, potentially due to a decreased use of parenteral penicillins, and be …
Amoxicillin-current use in swine medicine.
Burch DGS and Sperling D. J Vet Pharmacol Ther 2018 - Review. PMID 29352469
The ECOFF for amoxicillin against A. pleuropneumoniae is also 0.5 μg/ml demonstrating only a reduced susceptibility in 11.3% of isolates. ...Amoxicillin alone and in combination with clavulanic acid are currently classed together in Category 2 in the European Union. ...
The ECOFF for amoxicillin against A. pleuropneumoniae is also 0.5 μg/ml demonstrating only a reduced susceptibility in 11.3% of isola …
Optimal dose and duration of amoxicillin-plus-metronidazole as an adjunct to non-surgical periodontal therapy: A systematic review and meta-analysis of randomized, placebo-controlled trials.
McGowan K, et al. J Clin Periodontol 2018 - Review. PMID 29027242
CONCLUSION: There was no clinically meaningful difference between different doses or duration of amoxicillin-plus-metronidazole at 3 months post-treatment. ...Therefore, a 7-day regimen of 500/500 mg or 500/400 mg of amoxicillin and metronidazole would be most appropriate....
CONCLUSION: There was no clinically meaningful difference between different doses or duration of amoxicillin-plus-metronidazole at 3 …
Does the use of amoxicillin/amoxicillin-clavulanic acid in third molar surgery reduce the risk of postoperative infection? A systematic review with meta-analysis.
Menon RK, et al. Int J Oral Maxillofac Surg 2019. PMID 30145064
The risk of adverse effects was significantly higher in the amoxicillin-clavulanic acid group (RR=4.12, P=0.023) than in the amoxicillin group (RR 1.57, P=0.405). In conclusion, amoxicillin-clavulanic acid and amoxicillin may significantly reduce the risk of infection after third molar extraction. ...
The risk of adverse effects was significantly higher in the amoxicillin-clavulanic acid group (RR=4.12, P=0.023) than in the amoxi
Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study
Pasternak B, et al. BMJ 2018. PMID 29519881 Free PMC article.
PARTICIPANTS: 360 088 treatment episodes of fluoroquinolone use (78%ciprofloxacin) and propensity score matched comparator episodes of amoxicillin use (n=360 088). ...RESULTS: Within the 60 day risk period, the rate of aortic aneurysm or dissection was 1.2 cases per 1000 person years among fluoroquinolone users and 0.7 cases per 1000 person years among amoxicillin users. ...
PARTICIPANTS: 360 088 treatment episodes of fluoroquinolone use (78%ciprofloxacin) and propensity score matched comparator episodes of am
Microbial colonization of the periodontal pocket and its significance for periodontal therapy
Mombelli A. Periodontol 2000 2018 - Review. PMID 29193304
At present, for the therapy of any form of periodontal disease, there exists no protocol with proven superiority, in terms of efficiency or effectiveness, over scaling and root planing plus systemic amoxicillin and metronidazole. ...
At present, for the therapy of any form of periodontal disease, there exists no protocol with proven superiority, in terms of efficiency or …
Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics
Fallone CA, et al. Gastroenterology 2019 - Review. PMID 30998990
Second-line therapies should be bismuth quadruple therapy or levofloxacin triple therapy, depending on suspected resistance, reserving rifabutin-based triple and high-dose dual amoxicillin proton pump inhibitor therapy for subsequent treatment attempts. ...
Second-line therapies should be bismuth quadruple therapy or levofloxacin triple therapy, depending on suspected resistance, reserving rifab …
Direct oral amoxicillin challenge without preliminary skin testing in adult patients with allergy and at low risk with reported penicillin allergy.
Kuruvilla M, et al. Allergy Asthma Proc 2019. PMID 30582497
Although the most widely accepted protocol is penicillin skin testing, followed by oral amoxicillin challenge, time constraints and resources may preclude this. ...Direct oral amoxicillin challenge was recommended in patients with a history of benign rash, benign somatic symptoms, or unknown history associated with the last penicillin exposure >12 months ago. ...
Although the most widely accepted protocol is penicillin skin testing, followed by oral amoxicillin challenge, time constraints and r …
9,373 results
Jump to page
Feedback